SHTG recommendation

In response to enquiry from Scottish Diabetes Group

What were we asked to look at

We were asked to examine the evidence on using closed loop systems and the artificial pancreas for the management of type 1 diabetes. We were asked to consider the cost-effectiveness of these technologies compared with current diabetes management options, and to consider clinical effectiveness, safety and patient aspects.

Why is this important

Access to technologies to support people with managing diabetes is a key priority of the Scottish Government’s Diabetes Improvement Plan. The 2019 Scottish diabetes survey found that there were 33,452 people living with type 1 diabetes in Scotland. Living with type 1 diabetes is associated with a significant physical and mental health burden caused by the demands of managing the condition every day and worrying about future complications. Poorly controlled diabetes is associated with complications such as leg, toe or foot amputation, nephropathy, neuropathy and retinopathy resulting in sight loss. People with type 1 diabetes are also at increased risk of cardiovascular disease and premature mortality. Approximately 80% of the £10 billion annual spending on diabetes in the UK is used to fund the treatment of complications. Rapidly advancing diabetes technologies, such as closed loop systems and the artificial pancreas, have the potential to transform the lives of people living with type 1 diabetes. Demand for these technologies is increasing, with many people with type 1 diabetes anticipated to benefit from an artificial pancreas or closed loop system in the future.